The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Gregory Hemenway
No Relationships to Disclose
 
Eric Ross
Stock and Other Ownership Interests - Procter & Gamble
 
Candice Schwebel
No Relationships to Disclose
 
Lu Chen
No Relationships to Disclose
 
Efrat Dotan
Consulting or Advisory Role - Agenus; Amgen; Ipsen; Jazz Pharmaceuticals; Merck; Merus NV; Olympus; TME Therapeutics
Research Funding - Dragonfly Therapeutics (Inst); Ipsen (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lutris (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Zymeworks (Inst)
 
Fern Anari
No Relationships to Disclose
 
Pooja Ghatalia
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Andre Kydd
No Relationships to Disclose
 
Matthew Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - Adicet Bio; Exelixis; Merck; Piston Bio
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst)
 
Elizabeth Plimack
Consulting or Advisory Role - 23andMe; Abbvie; Adaptimmune; Astellas Pharma; AstraZeneca; Aura Biosciences; Bristol-Myers Squibb/Medarex; Daiichi Sankyo/Lilly; Eisai; EMD Serono; Flatiron Health; Merck; Pfizer; Seagen; Signatera; Urogen pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Daniel Geynisman
Honoraria - Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); CG Oncology (Inst); Harpoon therapeutics (Inst); Merck (Inst)